Feedback

Integrating Mechanisms in Thrombotic Peripheral Arterial Disease

Zugehörigkeit
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 6229 ER Maastricht, The Netherlands
Nagy, Magdolna;
ORCID
0000-0002-6532-2583
Zugehörigkeit
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 6229 ER Maastricht, The Netherlands
van der Meijden, Paola E. J.;
Zugehörigkeit
Cardiovascular Research, Bayer AG, 42117 Wuppertal, Germany
Glunz, Julia;
ORCID
0000-0001-7867-6957
Zugehörigkeit
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 6229 ER Maastricht, The Netherlands
Schurgers, Leon;
Zugehörigkeit
German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, 10785 Munich, Germany
Lutgens, Esther;
ORCID
0000-0001-7796-4463
Zugehörigkeit
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 6229 ER Maastricht, The Netherlands
ten Cate, Hugo;
Zugehörigkeit
Cardiovascular Research, Bayer AG, 42117 Wuppertal, Germany
Heitmeier, Stefan;
ORCID
0000-0002-3858-334X
Zugehörigkeit
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 6229 ER Maastricht, The Netherlands
Spronk, Henri M. H.

Peripheral arterial disease (PAD), a manifestation of systemic atherosclerosis, is underdiagnosed in the general population. Despite the extensive research performed to unravel its pathophysiology, inadequate knowledge exists, thus preventing the development of new treatments. This review aims to highlight the essential elements of atherosclerosis contributing to the pathophysiology of PAD. Furthermore, emphasis will be placed on the role of thrombo-inflammation, with particular focus on platelet and coagulation activation as well as cell–cell interactions. Additional insight will be then discussed to reveal the contribution of hypercoagulability to the development of vascular diseases such as PAD. Lastly, the current antithrombotic treatments will be discussed, and light will be shed on promising new targets aiming to aid the development of new treatments.

Zitieren

Zitierform:
Zitierform konnte nicht geladen werden.

Zugriffsstatistik

Gesamt:
Volltextzugriffe:
Metadatenansicht:
12 Monate:
Volltextzugriffe:
Metadatenansicht:

Rechte

Rechteinhaber: © 2022 by the authors.

Nutzung und Vervielfältigung: